10.02.20
8 min. read

Proteus founders explain. Investors talk DTx.

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Issue 072.

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week I published The Virgin Pulse Report. Thanks to everyone who sent in feedback. Here's what's happening this week:

  • I am working my way through some long write-ups of the DTx East event, which took place virtually in September. The first of a few quasi-transcripts of discussions at the event is below. I'll aim to do a few more for next week's edition.
  • In the past few weeks, Pear Therapeutics had a few customer announcements. One marked a new type of agreement for the company: The Hartford agreed to offer its employees Pear's reSET and reSET-O prescription digital therapeutics as covered benefits. PreferredOne, a health plan in Minnesota with 364,000 members also added the PDTs to its covered benefits.
  • Cognoa completed its 425-patient pivotal study for the company's "digital autism
×

Recent Articles